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Background: Endometrial cancer (EC) is a hormone-driven disease, and androgen receptor (AR) expression in high-grade EC
(HGEC) and metastatic EC has not yet been described.
Methods: The expression pattern and prognostic value of AR in relation to oestrogen (ERa and ERb) and progesterone (PR)
receptors, and the proliferation marker Ki67 in all EC subtypes (n¼ 85) were compared with that of healthy and hyperplastic
endometrium, using immunohistochemisty and qPCR.
Results: Compared with proliferative endometrium, postmenopausal endometrtial epithelium showed significantly higher
expression of AR (Po0.001) and ERa (P¼ 0.035), which persisted in hyperplastic epithelium and in low-grade EC (LGEC).
High-grade EC showed a significant loss of AR (Po0.0001), PR (Po0.0001) and ERb ( Po0.035) compared with LGEC, whilst
maintaining weak to moderate ERa. Unlike PR, AR expression in metastatic lesions was significantly (P¼ 0.039) higher than that in
primary tumours. Androgen receptor expression correlated with favourable clinicopathological features and a lower proliferation
index. Loss of AR, with/without the loss of PR was associated with a significantly lower disease-free survival (Po0.0001, Po0.0001,
respectively).
Conclusions: Postmenopausal endometrial epithelium acquires AR whilst preserving other steroid hormone receptors. Loss of AR,
PR with retention of ERa and ERbmay promote the unrestrained growth of HGEC. Androgen receptor may therefore be a clinically
relevant prognostic indicator and a potential therapeutic target in EC.
Endometrial cancer (EC) is the commonest gynaecological
malignancy in the developed world, with an increasing incidence
related to obesity (Cancer Research UK, 2013; Lindemann et al,
2010). Traditional classifications of EC are based either on clinical
and endocrine features (e.g., types I and II; Bokhman, 1983) or on
histopathological characteristics (e.g., endometrioid, serous and
clear-cell carcinomas, and carcinosaroma; Murali et al, 2014).
More recently, a molecular classifier that can be combined with
clinicopathological features to predict outcome has also been
proposed (Kandoth et al, 2013; Talhouk et al, 2015) In contrast
with previous reports, recent data suggest that type I and II ECs
may share common aetiological factors, including their response
to/stimulation by oestrogen and other ovarian steroid hormones
(Setiawan et al, 2013).
The endometrium is the main target organ for ovarian
hormones, and steroid hormones are implicated in carcinogenesis
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in endometrium and other classical hormone-responsive tissues
such as breast and prostate. Endometrial cancer is generally a
disease of the postmenopausal (PM) period that is defined by
cessation of the cyclical production of ovarian hormones. As these
hormones exert their effect via their cognate receptors, in common
with other hormone-responsive cancers such as breast cancer
(Tagnon, 1977; Thike et al, 2001), the hormone receptor status of
ECs would be expected to have a role in predicting clinical
outcome and guiding therapeutic choice (Zhang et al, 2015).
Unlike breast cancer (Breast Cancer Consensus C et al, 1994),
steroid receptor status is not routinely reported for EC, yet
increasingly clinical oncologists in the UK seek this information in
high-grade EC to make therapeutic decisions beyond standard
surgery (Singh et al, 2007).
Defining the contribution of all steroid receptors (including AR,
which has not been described in detail in EC previously), to the
initiation, progression and prognosis of EC will improve the
understanding of the hormonal changes that precede and
potentially drive EC tumorigenesis.
In this study, the spatial and temporal expression pattern of AR
in normal and hyperplastic PM endometrium was compared with
that of healthy proliferative phase (PP) endometrium. The
expression profile of AR in EC was investigated and compared
with endometrium from healthy PM women. Expression of AR,
ERa, ERb, PR and the proliferation marker Ki67 was correlated in
normal (premenopausal PP and PM), hyperplastic and malignant
endometrium to gain a better insight in to the interplay between
oestrogens, progesterone and androgens in healthy and neoplastic
endometrium. Finally, the prognostic value of AR and other sex
hormone receptors in EC was evaluated.
MATERIALS AND METHODS
Patient population. Patient groups are detailed in Table 1. A total
of 85 EC, 16 metastatic lesions (3 lymph node, 7 soft tissue, 3
parametrium and 3 omentum), 12 hyperplastic (4 without
cytological atypia, EHNA; 8 with cytological atypia, EHA) and
28 full-thickness normal endometrial biopsies were collected from
patients undergoing hysterectomy in Liverpool Women’s Hospital
and Lancashire Teaching Hospitals Trusts from 2009 to 2014. The
study was approved by Liverpool and Cambridge Adult Research
Ethics Committee (LREC 09/H1005/55, 11/H1005/4 and CREC 10/
H0308/75). The histological type and grade of EC specimens were
assigned by experienced gynaecological pathologists according to
the International Federation of Gynecology and Obstetrics (FIGO;
Zaino et al, 1995). Endometrial cancer was categorised as low-
grade (LGEC, including grade 1 and grade 2 endometrioid EC) or
high-grade tumours (HGEC, including grade 3 endometrioid,
serous and clear-cell carcinomas, and carcinosarcoma) (Voss et al,
2012) for subsequent analysis of immunohistochemistry (IHC)
data (Table 1). Proliferative phase specimens were assigned
according to last menstrual date and histological criteria (Noyes
et al, 1950; Dallenbach-Hellweg et al, 2010). All samples were split
in to two; one was fixed (X24 h in 4% (v/v) buffered formalin) and
paraffin-embedded for immunohistochemical staining, and the
other part was immediately placed into RNAlater (Sigma, Dorset,
UK) for RNA extraction for PCR.
Patient clinicopathological and demographic details were
retrieved by review of hospital notes and clinical databases. None
of the patients received hormonal treatments, chemotherapy or
pelvic radiation before surgery.
Immunohistochemistry. After antigen retrieval at pH6 as pre-
viously described (Hapangama et al, 2012) 3 mm formalin-fixed
paraffin-embedded tissue sections were immunostained with anti-
human steroid receptor antibodies and Ki67; antibody sources,
concentrations and incubation conditions are detailed in
Supplementary Table 1. Detection was with the ImmPRESS
polymer-based system and visualisation was with ImmPACT
DAB (Vector Laboratories, Peterborough, UK) used in accordance
with the manufacturer’s instructions. Sections were lightly
counterstained in Gill 2 Haematoxylin (Thermo Scientific,
Runcorn, UK), dehydrated, cleared and mounted in synthetic
resin. Matching isotype (0.5mgml) replaced the primary antibody
as a negative control, with internal positive controls performed in
each staining run.
Analysis of IHC staining. Immunostaining for the four steroid
receptors was assessed semi-quantitatively using a four-tiered
Liverpool endometrial steroid quick score (LESQS). The final score
out of 12 was calculated by multiplying the proportion of positive
cells (1–10%¼ 1, 11–20%¼ 2, 21–40%¼ 3 and 440%¼ 4) by the
staining intensity categories (0¼ no staining, 1¼weak, 2¼
moderate and 3¼ strong). The detailed description, optimisation
and validation of this scoring system are presented in
Supplementary Methods. The Ki67 proliferative index (PI) was
evaluated as the percentage of immunopositive cells, of any
Table 1. Demographic features of study groups
Study groups Number of cases % Agea (years) BMIb (kgm2)
Proliferative phase 14 39 (30–47) 26.7 (17.5–45.5)
Postmenopausal 14 68.5 (57–79) 26.3 (22.7–35.8)
Endometrial hyperplasia 12 50 (37–67) 29.7 (34.3)
Without cytological atypia 4 55 (50–62) 25.75 (23.6–53.2)
With cytological atypia 8 52 (37–67) 34 (27.9–57.8)
Endometrial cancer 85 67 (41–89) 30 (20.2–54.4)
LGEC 37 43.5 63.5 (41–84) 30.8 (21.6–46.1)
Grade1 endometrioid 19 22.4 63 (46–84) 35.7 (21.6–46.1)
Grade2 endometrioid 18 21.2 63.5 (41–83) 29 (22.3–54.4)
HGEC 48 56.5 70 (51–89) 29.6 (20.2–54.4)
Grade3 endometrioid 15 17.6 69 (51–83) 26.7 (22.1–42.7)
Serous 7 8.2 68 (64–82) 29.5 (24.8–34.9)
Clear cell 12 14.1 69 (52–82) 29.9 (25.4–31.5)
Carcinosarcoma 14 16.5 54.5 (59–89) 28.6 (20.2–37.2)
Metastatic lesions 16 68 (41–89) b
Abbreviations: BMI¼body mass index; HGEC¼ high-grade endometrial carcinoma; LGEC¼ low-grade endometrial carcinoma.
aData expressed as median (range).
bBMI data were available for only 60 cases.
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intensity. The entire section was evaluated at  400 magnification
as previously described (Al Kushi et al, 2002).
Epithelial and stromal cell staining was scored separately in PM,
and malignant endometrium and stratum basalis of healthy PP
endometrium by two independent observers (AMK and DKH).
Discrepencies between the two observers were resolved by re-
evaluating the samples together and agreeing on a final score.
For the purpose of description, scores 1–4 were considered as
low, 5–8 as moderate and 9–12 as high levels of expression. For
survival analysis and correlation with clinicopathological analysis,
data were subclassified as immunopositive when 410% of the
neoplastic cells expressed the target protein at any intensity
(LESQS X2) and immunonegative if o2 (Pertschuk et al, 1996).
RT–qPCR. Total RNA from tissue samples was extracted using
TRIzol Plus RNA Purification System (Life Technologies, Paisley,
UK), and quantified by NanoDrop ND-1000 (Thermo Fisher
Scientific, Loughborough, UK). Total RNA was reverse transcribed
using AMV First Strand cDNA synthesis kit (New England Bio
Labs, Hertfordshire, UK) after DNase treatment (DNase I
(#M0303), New England Bio Labs, Hertfordshire, UK), using the
manufacturer’s protocol. cDNA was amplified by qPCR using
JumpStart SYBR Green supermix (Sigma, Dorset, UK ) and the
Light Cycler 96 Roche Real-Time System (Roche Diagnostics Ltd.
BurgessHill, UK). Primers are listed in Supplementary Table 2.
Relative transcript expression was calculated by the DDCT method,
normalised to the reference gene YWHAZ (Sadek et al, 2011) using
Biogazelle qbaseþ software (Biogazelle NV, Zwijnaarde, Belgium)
Statistical analysis. Statistical differences between groups were
calculated by non-parametric tests (Kruskal–Wallis and/or Mann–
Whitney U-test or Wilcoxon signed-rank test) using Statistical
Package for the Social Sciences (SPSS) version 21 (IBM Corp,
Armonk, NY, USA). Descriptive values were presented as median
and range. The correlations between immunoexpression scores were
examined with Spearman test, and association between immuno-
scores and the multiple clinicopathological parameters with Pearson
w2. Disease-free survival (DFS) was calculated from the date of
surgery to the date of recurrence, death or the date on which the
patient was last seen. For survival analysis each parameter was
categorised, and survival curves were obtained using the Kaplan–
Meier method. The Cox proportional hazards regression model was
used to identify the independent prognostic factors. Only variables
with Po0.05 in the univariate analysis were included in the
multivariate model. Po0.05 was considered significant.
RESULTS
Demographic data. Patient demographics are detailed in Table 1.
Women with HGEC were significantly older than those with LGEC
(Po0.0001). Patients with EHA were significantly younger than
those with LGEC (P¼ 0.016). Healthy PM controls had the lowest
BMI compared with women who had EHA (P¼ 0.007) and LGEC
(P¼ 0.022). There was no significant difference in BMI between
LGEC and HGEC.
IHC analysis of AR and other steroid receptor expression. All
four steroid receptors were expressed by the endometrium
(Figure 1). The main focus of interest, AR, was expressed by both
the epithelium and stroma. At a subcellular level, both cytoplasmic
and nuclear AR staining was observed; only nuclear immunostain-
ing suggesting transcriptionally active AR with functional relevance
was scored and semi-quantified.
Healthy PM endometrial epithelial cells aquire AR and preserve
ERs and PR. The dominant steroid receptor in both epithelium
and stroma of the healthy endometrium was PR. In PP
endometrium, AR expression was largely limited to stromal cells
in both the stratum basalis and functionalis with absent epithelial
AR staining (Supplementary Figure 1a). In contrast, the most
striking feature of non-proliferating PM endometrium was the
emergence of nuclear AR immunopositivity (Po0.001) in the
epithelial cells (Figure 2A). Compared with epithelial cells in PP
stratum basalis, PM epithelial cells also expressed significantly
higher levels of ERa (P¼ 0.035) (Figure 2C and Supplementary
Table 3); however, there were no differences in ERb and PR
expression scores or in the ERa/ERb ratio. The stromal expression
scores for both PM and PP stratum basalis were similar for all the
steroid receptors examined (Supplementary Table 3).
AR expression and ERa/ERb ratio is increased in atypical
endometrial hyperplasia. PR expression was the strongest of the
steroid receptors in both epithelial and stromal compartments of
EH (Supplementary Table 3). Interestingly, compared with PP
epithelium, nuclear AR expression was significantly higher in the
epithelial cells in EHA (P¼ 0.025), but no significant change was
observed when compared with PM epithelium (Figures 2A and C).
Endometrial stroma in EHA showed significant loss of AR
expression compared with PP stroma (Po0.0001). The general
trend of ERa epithelial expression in EHA was higher than that of
PP (P¼ 0.076) and PM (P¼ 0.547). In contrast, the trend of ERb
expression in EHA was lower than that of PP (P¼ 0.128) and
significantly lower compared with PM endometrium (P¼ 0.014,
Figure 2C). Thus, ERa/ERb in EHA was generally higher than that
of normal endometrium; this was significant compared with PP
(P¼ 0.041).
In common with AR, both ERa (P¼ 0.043) and ERb (P¼ 0.045)
expression scores were significantly decreased, whereas PR was
increased (P¼ 0.02) in the stroma of EHA compared with PM
endometrium. Epithelial PR expression levels were preserved at a
level that was comparable to that of healthy PP and PM samples.
The PI, assessed by Ki67 immunopositivity, of epithelial cells in
EHNA and EHA was similar to that of PP epithelium but, as
expected, was significantly higher than PM epithelium (EHNA
P¼ 0.016, EHA P¼ 0.017, Supplementary Figure 1b).
AR, PR and ERb are downregulated in HGEC. We chose healthy
PM tissue as the healthy comparator for steroid receptor expression
scores of EC samples. ERb was the predominant steroid receptor
expressed in both LGEC and HGEC (Figures 1 and 2C). AR
(P¼ 0.10, Figures 1 and 2A and C) and ERa (P¼ 0.05, Figure 2C)
staining scores showed a trend to being increased in LGEC, with
simultaneous reduction in PR (P¼ 0.08, Figure 2C). This was
associated with a significant reduction in stromal expression of AR
(Po0.0001, Figure 2B), ERa (Po0.0001) and PR (Po0.0001) when
compared with healthy PM controls. There was no significant change
in ERb scores (stromal and epithelial) of LGECs compared with
healthy controls, although the ERa/ERb ratio was higher in LGEC
compared with PP (Po0.0001); and PM (P¼ 0.02).
The epithelial cells of HGEC and the surrounding stroma
showed a general reduction in the expression of all four steroid
receptors compared with healthy PM tissue (Supplementary
Table 3). Compared with LGEC, in HGEC epithelial AR
(Po0.0001), PR (o0.0001) and ERb (P¼ 0.035) scores were
significantly lower (Figures 1 and 2A and C). Within the subtypes
of HGEC, the most pronounced loss of AR was observed in the
clear-cell carcinoma group (P¼ 0.001); albeit ERa expression
scores in the same group remained moderate to strong (Figure 2D).
Weak to moderate cytoplasmic AR was observed in 33% (11 out of
33) HGEC in the absence of nuclear staining (Figure 1, serous).
The expression scores for both PR (Po0.0001) and ERb (P=0.003)
in HGEC epithelial cells and surrounding stroma PR (Po0.0001)
and ERb (P¼ 0.02; Figure 2C) were significantly lower than
healthy PM counterparts. Interestingly, in non-endometrioid
HGEC, 26 out of 33 (78.8%) showed loss of PR whilst all were
ERbþ , and 30 out of 33 (90.9%) were also ERaþ . Progesterone
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receptor loss was limited to only 5 out of 15 (33.3%) of the
endometrioid HGEC. Expression of AR in non endometrioid
HGEC was comparable to PR; 16 out of 33 (48.5%) were AR-
negative, and 13 of these were also negative for PR. Furthermore,
only AR expression (not PR) reduced significantly with advanced
FIGO stage (stage I vs stage III, P¼ 0.006, Figure 2E).
Metastatic lesions aquire AR. Nuclear AR was observed in 10 out
of 16 (62.5%) (Figure 3A) metastatic lesions, and expression scores
were significantly higher compared with the matched primary
lesions (P¼ 0.03). By contrast, only 6 out of 15 (40%) (Figure 3B)
of metastatic lesions expressed PR. Although the median expres-
sion of Ki67 was generally lower in metastatic lesions (45%) than in
the matched primary tumour (60%) (Supplementary Figure 1b; E
and F), the difference in the expression pattern of both PR and
Ki67 between the two groups was not statistically significant
(Figure 3C).
AR expression positively associates with favourable prognostic
factors. Endometrial cancer epithelial AR correlated positively
with PR (r¼ 0.63, Po0.0001), whilst there was a negative
correlation with Ki67 (r¼  0.43, P¼ 0.0004, Supplementary
Table 4). When expression of steroid receptors (as positive or
negative) was correlated with each clinicopathological parameter,
both AR and PR expression correlated positively with well-
differentiated tumours and those without cervical invasion, yet
only AR expression showed positive correlation with early FIGO
stages (P¼ 0.048, Supplementary Table 5). Intriguingly, concurrent
loss of AR and PR showed a significant positive correlation with
higher tumour grades (Po0.0001), late FIGO stages (P¼ 0.004),
deep myometrial invasion (P¼ 0.003), extrauterine invasion
(P¼ 0.048) and cervical invasion (Po0.0001). ERa did not show
a significant correlation with clinicopathological parameters;
however, a high ERa/ERb ratio was associated with invasion of
the cervical stroma (P¼ 0.041) and showed a trend to be associated
with advanced stage tumours (P¼ 0.057).
Loss of AR adversely influences patient outcome. Follow-up data
were available for all EC patients. By January 2015 the median
follow-up was 19 months, ranging between 6 and 40 months.
During the follow-up period there were 5 recurrent tumours and
16 deaths (13 as a result of disease progression and 3 from other
causes). ERa and ERb expression did not show a significant
association with clinical outcome. A significant reduction in DFS
was identified in the AR-negative group (P¼ 0.0001) and PR-
negative group (P¼ 0.005). A subset of EC, which was negative for
both AR and PR, showed a further decline in DFS (Po0.0001).
Moreover, patients with a high ERa/b ratio had a worse prognosis
(DFS, P¼ 0.023) than those with a low ERa/b ratio (Figure 4).
Univariate analysis has shown that HGEC, advanced stages (III
and IV), deep myometrial invasion, cervical invasion, loss of AR,
loss of PR, combined AR/PR loss and high ERa/ERb ratio were
significantly associated with progressive disease (Table 2). None of
the other parameters was significantly associated with patient
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outcome. Furthermore, Cox regression model confirmed that only
AR (P¼ 0.007), ERa/ERb (P¼ 0.032), tumour grade (P¼ 0.047)
and myometrial invasion (P¼ 0.008) were independent prognostic
indicators (Table 2).
Steroid receptor mRNA levels reflect their protein expression.
Consistent with the IHC results, a general decline in mRNA levels
for all steroid receptors was observed in HGEC. This reduction was
significant for AR (P¼ 0.0002) when compared with PM
endometrium, and for ERa (P¼ 0.003) when compared with
LGEC. PR transcript level in HGEC was significantly lower than
both PM (P¼ 0.0002) and LGEC (P¼ 0.001). The change in ERb
mRNA was not significant (Figure 2F). Furthermore, AR (r¼ 0.59,
P¼ 0.015) and PR (r¼ 0.74, P¼ 0.001) mRNA levels also showed a
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significant correlation with their protein expression scores (data
not shown).
DISCUSSION
To our knowledge, this is the first comprehensive report
comparing AR expression in healthy PM endometrium with
healthy premenopausal PP endometrium and all EC subtypes,
including non-endometrioid type II (serous and clear-cell carci-
nomas and carcinosarcoma) ECs and metastatic lesions. We have
also described the contemporaneous expression scores for ERa,
ERb and PR in serial sections of the same endometrial samples,
allowing inferences to be made regarding their functional interplay
in both healthy endometrium and in endometrial carcinogenesis.
Previous reports of steroid receptor protein expression in
normal and pathological endometrium have used different semi-
quantification methods (Mertens et al, 2001; Critchley et al, 2002;
Mylonas et al, 2007; Zannoni et al, 2013). Of the available
quickscores, Allred and IRS have been commonly used to analyse
steroid receptors in endometrium (Mylonas et al, 2007; Zannoni
et al, 2013), but these two systems were optimised for ER and PR
expression (not AR) specifically in breast tissue. We propose a
LESQS, which is optimised for both normal and neoplastic
endometrium. Importantly, LESQS had the best correlation with
a standard H-score for AR and ERa compared with both Allred
and IRS scores for either epithelial or stromal compartments.
LESQS also showed high correlation with the H-score for PR and
ERb, similar to the Allred score correlation (Supplementary
Table 6). In order to gain better insight into hormone actions, all
cognate steroid receptors (AR, ERa, ERb and PR) need to be
assessed using the same scoring system; hence the optimised
LESQS was chosen.
Postmenopausal endometrium is composed of inactive glands
lying in a compact stroma that morphologically resembles the
stratum basalis of premenopausal endometrium (McCluggage,
2011). Moreover, PM endometrium is characterised by the
complete loss of the stratum functionalis; therefore, we compared
the steroid expression in PM endometrium with that of PP stratum
basalis. Interestingly, compared with PP stratum basalis, we found
significantly higher levels of epithelial AR and ERa in PM
endometrium but similar ERb and PR expression levels. Horie
et al (1992) reported AR expression (albeit in a sample size of
n¼ 4) in PM endometrial epithelium, which is consistent with our
results, but they indicated the AR expression levels to be similar to
PP stratum basalis. Their use of a small sample size without
quantifying the immunostaining may explain the differences in
conclusion between the two studies. In contrast, a previous report
comparing PM endometrium with PP stratum functionalis
suggested a decrease of ERa, ERb and PR expression in PM
epithelial cells (Mylonas et al, 2007). The PM hormonal milieu is
characterised by the absence of progesterone and oestradiol, the
presence of low levels of circulating oestrone (Sivridis and
Giatromanolaki, 2004) and persisting levels of androgens from
the adrenals, which may support the maintenance of endometrial
PR and ER expression. Although there are reports suggesting focal
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Figure 4. Kaplan–Meier survival curve for the probability of disease-free period relative to immunoexpression of (A) AR, (B) PR, (C) AR/PR
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Table 2. Univariate and multivariate analyses of disease-free
survival
Variables Univariate Multivariate
P P HR (95% CI)
Age (years): p65 vs 465 0.328 Removed —
BMIa: p30 vs 430 0.531 Removed —
Tumour stage: I–II vs III–IV 0.029 0.579 —
Tumour grade: LG vs HG 0.005 0.046 5.5 (1.0–29.8)
Lymphovascular invasion:
 vs þ
0.097 Removed —
Myometrial invasion : p50% vs
450%
0.002 0.008 8.8 (1.8–44.2)
Cervical stromal invasion: – vs þ 0.0001 0.073 —
Extra uterine invasion:  vs þ 0.19 Removed —
AR expression: – vs þ 0.001 0.007 0.12 (0.3–0.5)
PR expression: – vs þ 0.012 0.771 —
ARPR expression: – vs þ 0.001 0.727 —
ERa expression: – vs þ 0.547 Removed —
ERb expression: – vs þ 0.895 Removed —
ERa/b ratio: p1 vs 41 0.031 0.032 3.5 (1.1–11.3)
Abbreviations: AR¼ androgen receptor; BMI¼body mass index; CI¼ confidence interval;
ER¼oestrogen receptor; HG¼high grade; HR, hazard ratio; LG¼ low grade; PR¼
progesterone receptor.
aData were available for 60 patients only.
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and weak epithelial AR expression appearing in late secretory
phase endometrium, presumed to be associated with progesterone
withdrawal (Horie et al, 1992; Mertens et al, 2001), the most
prominent feature of premenopausal secretory phase endometrium
is the high levels of stromal AR expression. This is in contrast with
PM endometrium, where dominant AR staining is in the
epithelium. Furthermore, anti-progesterone (mifepristone) admin-
istration was associated with upregulation of both stromal and
epithelial AR expression in premenopausal primate endometrium
(Slayden and Brenner, 2004), yet we observed the stromal AR to be
low in PM compared with PP endometrium. As by definition, PM
endometrium has not been exposed to progesterone for at least 12
months, the appearance of epithelial AR in PM endometrium
cannot be equated merely to progesterone withdrawal. To
complicate matters further, mifepristone is not only a progesterone
antagonist but also has anti-androgenic and glucocorticoid
properties (Hapangama, 2003). Therefore, the appearance of AR
in PM epithelium may be induced by the action of either oestrone
via ERa or androgens via AR (Fujimoto et al, 1994; Lovely et al,
2000). Interestingly, the upregulation of PM epithelial AR was not
associated with high cell proliferation (assessed by Ki67), which
would be expected to be present with classical ERa-mediated
epithelial action. Short-term treatment with testosterone was
associated with low PI in normal PM women (Zang et al, 2007).
Consistent with in vitro studies (Tuckerman et al, 2000; Gibson
et al, 2014), this indicates a direct androgen-driven induction of
AR, resulting in an inhibition of PM epithelial proliferation. Taking
in account that stromal AR has been described to have an
antiapoptotic role (Marshall et al, 2011), AR seems to have a cell-
specific function in the endometrium.
Endometrial hyperplasia with atypia is a premalignant condition
(Lacey et al, 2008) with molecular aberrations (Steinbakk et al,
2011) and morphological changes that are typical for unopposed
oestrogenic activity. Consistent with previous reports, the epithelial
expression of AR in EHA was higher than that in PP endometrium
(Ito et al, 2002), whereas the PI of EHA did not differ from that of
PP endometrium. Intriguingly, compared with PM endometrium,
AR scores were relatively lower in EHA, with a significantly high
Ki67 confirming oestrogen-driven cell proliferation.
The available data on steroid receptor expression in EC subtypes
are largely confined to endometrioid EC focusing on ERa, ERb and
PR (Deligdisch et al, 2000; Kounelis et al, 2000; Collins et al, 2009).
Traditionally, type II ECs are considered to be hormonally
independent; there are only limited reports of ER and PR
expression (Alkushi et al, 2010; Mhawech-Fauceglia et al, 2013),
with no previous data on AR and ERb expression in serous and
clear-cell carcinomas and carcinosarcomas (Hapangama et al,
2015). However, recent reports indicate that both type I and II ECs
have similar risk factors (Setiawan et al, 2013). Studies describing
AR expression in endometrioid EC are scarce and inconsistent.
Horie et al (1992) reported positive AR expression in four grade 2
EC samples. In our study, most LGECs expressed AR (protein and
transcript), and the LGEC immunoscores did not significantly
differ from those of PM controls. Grade 3 endometrioid EC,
however, expressed lower levels of AR consistent with the previous
report (Ito et al, 2002). Conflicting reports have suggested that AR
is absent in 72% ECs (Sasaki et al, 2000), although, in that
particular study, the specific histological type was not described for
all samples. In agreement with our results, others have reported
downregulation of PR in non-endometrioid HGEC (Alkushi et al,
2010). Interestingly, in comparison with LGECs, HGEC showed a
significant decline of both PR and AR protein expression, whereas
the decrease in ERa was not significant. This was particularly
evident in clear-cell carcinoma, although conflicting reports have
shown a reduction of ER (without distinguishing ERa or ERb
subtypes) in clear-cell EC (Hoang et al, 2013; Mhawech-Fauceglia
et al, 2013). Differences in sample size and methodology
(antibodies and immunoanalysis) are likely to be the explanation
for this discrepancy. In agreement with our data, the recent TCGA
data also suggest AR expression to be a feature of LGECs with
better prognosis (Kandoth et al, 2013). Furthermore, it was
interesting that although ESR1 (ERa) and PGR (PR) gene mutation
was seen in endometrial cancers with favourable outcome, AR
mutations were not identified in the large TCGA data set,
suggesting the therapeutic potential of AR receptor modulators
in EC.
From these results, it is tempting to speculate that even in
presumed ‘hormonally independent’ non-endometrioid HGEC,
ERa and ERb receptors were expressed relatively abundantly (with
concomitant loss of AR and PR), resulting in possible unopposed
oestrogenic activity.
Our data examined AR expression in metastatic lesions for the
first time, and demonstrated significantly higher AR expression
than in the matched primary tumours. Although molecular and
biological characteristics of macro-metastases are not well defined,
endometrial metastatic epithelial cells have been reported to
express oestrogen receptors, ERb in particular (Fujimoto et al,
2002). The metastatic lesions examined in the present study
showed some similarities with the primary tumours such as the PR
expression and PI. Sixty per cent of these lesions showed loss of PR,
consistent with previous reports (Tangen et al, 2014) but
interestingly, in these lesions, AR expression was significantly
upregulated. Low PR expression may explain the poor clinical
response observed in a majority (66%) of patients with recurrent or
metastatic tumours to progesterone treatment (Fiorica et al, 2004).
The re-emergence of AR expression in these lesions, however,
produces a possible novel adjuvant therapeutic opportunity.
Unlike breast cancer, the literature on the prognostic value of
ERa, ERb, ERa /ERb ratio and PR in EC is inconsistent, probably
owing to methodological variations (Takama et al, 2001; Fujimoto
et al, 2002; Shabani et al, 2007; Jongen et al, 2009; Zannoni et al,
2013). Our results have shown that AR and PR expression is
associated with longer DFS in patients with EC, and this is
consistent with other recent reports (Tanaka et al, 2014; Tangen
et al, 2014), and concurrent loss of both AR and PR was associated
with a higher risk of relapse. Moreover, loss of AR and PR
correlated positively with unfavourable clinicopathological para-
meters that predict poor clinical outcome such as high-grade, deep
myometrial invasion and cervical stromal involvement, and
advanced FIGO stages. AR may also bind progesterone, which is
the main hormonal therapy in EC, and subsequently may mediate
inhibition of cell proliferation (Hackenberg and Schulz, 1996).
Further, emerging evidence indicates that androgens, unlike
progestin, may induce PR expression (Park et al, 2014). Therefore,
besides the prognostic significance, expression data on AR and PR
may be a useful clinically as a potential therapeutic target to tailor
adjuvant hormonal therapy for intermediate and higher-risk EC.
We have also shown a high ERa/ERb ratio to be significantly
associated with shorter DFS, and this is likely to be due to a relative
reduction in expression of the guardian protein, ERb, that
counteracts mitogenic ERa activity (Hapangama et al, 2015).
These data conflict with some previous reports that only examined
endometrioid EC, using either mRNA levels or different quanti-
fication methods of IHC staining (Takama et al, 2001; Zannoni
et al, 2013).
We acknowledge that this is an observational analytic study,
which requires further functional and genetic investigations in the
future to confirm the clinical relevance of these findings. Further
work will also evaluate the potential therapeutic effects of selective
AR modulators in the management of advanced EC. Further, we
believe that the characterisation of metastatic lesions for steroid
receptor expression in a larger sample series ideally before and
after hormonal therapy may unveil the reasons behind the limited
responsiveness of EC to hormonal therapy. Our LESQS scoring
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system will provide a standard and clinically applicable tool for
researchers to undertake these important future studies.
CONCLUSIONS
Healthy PM endometrial epithelial cells acquire AR compared with
healthy premenopausal proliferative endometrium, whilst ERa,
ERb and PR expression is maintained. Nuclear epithelial AR
expression appears to be associated with an anti-proliferative
phenotype suggesting a cell-type-specific function of androgen. In
EC, loss of AR and PR with persistent ERa and ERb expression
may promote the unrestrained growth and propagation observed
in HGEC. Therefore, ER subtypes may potentially represent a
therapeutic target in HGEC, whilst AR may be a clinically relevant
prognostic indicator.
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